Mifepristone for induction of labor

Archil Khomasuridze, Ludmila Barbakadze, Lali Pkhaladze


Introduction: Mifepristone is a compound, called “Abortion Pill”, because, it causes termination of unwanted pregnancies in an easy way in the most of cases. Especially effective Mifepristone is in combination with prostaglandins (Misoprostol). Mifepristone is commonly used by us in obstetrics during the last 15 years and our experience is based on the data of thousands of patients. In this review, article we decided to draw the attention to the abilities of the Mifepristone during the labor.  Myfepristone has been used in different groups with different purposes and the results shoved high efficacy of this method: II Trimester Surgical Abortion (by Medical and Social Indications), or due to Fetal Death and Malformations - 96,7%; Induction of Labor in III Trimester due to Fetal Death - 87,9%; Induction of Labor in III Trimester due to Fetal Malformations - 89,3%; Induction of Labor due to Pregnancy Prolongation more than 42 weeks - 82,3%; Preterm rupture of  Membranes – 92,4%; Weakness of labor on  the background  of unripe cervix - 83,3%; During  Physiologic  Labor  for  cervical  ripening - 95%. In Total the efficacy of Myfepristone was - 92,8 %.

In cases of using of Mifepristone during physiological labor the lesions of cervix prominently decreased and then disappeared completely. According to the monitoring of physiological labor of 541 patients during the last 1,5 year Myfepristone shoved adequately cervix ripening and pain killing effect. After usage of Mifepristone no cervical lacerations was revealed, hypotonic bleeding and amount of blood loss during labor were significantly low compared with controls.

Method: The data concerning the issue was collected from the Google, NCBI and PubMed database by the use of keywords, such as: Antiprogesterone; Mifepristone; Termination of pregnancy; Labour induction. The years for search were 1982-2018. The results of several studies were conducted in Georgia between 2002-2008.

Conclusion: Antiprogesterone -Mifepristone is an effective remedy for cervical maturation and control of weakness of birth activity; after application of Mifepristone cervical maturation and active contraction of uterus is painless.


Antiprogesterone; Mifepristone; Termination of pregnancy; Labour induction.

Full Text:



Heilig S. The ‘Abortion Pill’: Ru 486: A Woman's Choice, Etienne-Emile Baulieu with Mort Rosenblum. New York: Simon & Schuster, 1991238 PP.(Available in the original French edition as Generation pilule.). Cambridge Quarterly of Healthcare Ethics. 1992;1(3):281-2.

Herrmann W, Wyss R, Riondel A, Philibert D, Teutsch G, Sakiz E, Baulieu EE. The effects of an antiprogesterone steroid in women: interruption of the menstrual cycle and of early pregnancy. Comptes rendus des séances de l'Académie des sciences. Série III, Sciences de la vie. 1982 May;294(18):933-8

Chen MJ, Creinin MD. Mifepristone with buccal misoprostol for medical abortion: a systematic review. Obstetrics & Gynecology. 2015 Jul 1;126(1):12-21.

Wildschut H, Both MI, Medema S, Thomee E, Wildhagen MF, Kapp N. Medical methods for mid‐trimester termination of pregnancy. Cochrane Database of Systematic Reviews. 2011(1).

He QJ, Yang B, Wang WF, Wu HH, Fang RY. Synergistic effects of DL111-IT in combination with mifepristone and misoprostol on termination of early pregnancy in preclinical studies. Contraception. 2003 Oct 1;68(4):289-95.

Fiala C. Exelgyn,(February 2006)." Mifegyne UK Summary of Product Characteristics (SPC)" Retrieved on 4-4-08.

Food and Drug Administration. Mifeprex (mifepristone) information. Silver Spring, MD: Food and Drug Administration; 2016. .

Bagaria M, Suneja A, Vaid NB, Guleria K, Mishra K. Low‐dose mifepristone in treatment of uterine leiomyoma: A randomised double‐blind placebo‐controlled clinical trial. Australian and New Zealand Journal of Obstetrics and Gynaecology. 2009 Feb;49(1):77-83.

Trussell J, Wynn L. Dedicated emergency contraceptive pills worldwide. Princeton: Office of population research at Princeton University. 2007.

Von Hertzen H, Piaggio G, Peregoudov A, Ding J, Chen J, Song S, Bártfai G, Ng E, Gemzell-Danielsson K, Oyunbileg A, Wu S. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial. The Lancet. 2002 Dec 7;360(9348):1803-10.

Ciato D, Mumbach AG, Paez-Pereda M, Stalla GK. Currently used and investigational drugs for Cushing s disease. Expert opinion on investigational drugs. 2017 Jan 2;26(1):75-84.

Khomasuridze A. Mifepristone for Postcoital Contraception. InReproductive Medicine for Clinical Practice 2018 (pp. 149-153). Springer, Cham.

Hapangama D, Neilson JP. Mifepristone for induction of labour. Cochrane Database of Systematic Reviews. 2009(3).

Athawale R, Acharya N, Samal S, Hariharan C. Effect of mifepristone in cervical ripening for induction of labour. Int J Reprod Contracept Obstet Gynecol. 2013 Mar;2(1):35-8.

Khomasuridze A, Parkauli M. Evaluation of Efficiency of Various Methods of Interruption of Pregnancy in II Trimester. Annals of Biomedical research and education. 2003 Oct;3(4):231-8.. Vol. 3.Issue 4.

Tsertsvadze G, Ungiadze J,Kochev D, Parkauli M. The use of Pencrofton for the induction of uterine contraction in case of intrauterine fetal death. Reproductive Health of Children and Adolescence. 2005; (5): 22-8. Russian article.

Lockwood CJ. ACOG Guidelines: Management of Late-Term and Postterm Pregnancies.

Morantz C, Torrey B. Management of postterm pregnancy. American Family Physician. 2004;70:1808-10.


  • There are currently no refbacks.


Become a REVIEWER 


ISSN: 2346-8491 (online)